A method for dissolving scars comprises administering dextran sulfate, or a pharmaceutically acceptable salt thereof, to a subject suffering from fibrosis or a fibrotic disease, disorder or condition to dissolve an established scar in the subject.

Pharmaceutical compositions and methods for treating ocular disorders in a subject, which include betamethasone or a pharmaceutically acceptable salt thereof at a concentration of 0.01% w/w to 0.08% w/w, mycophenolic acid or a pharmaceutically acceptable salt thereof at a concentration of 0.05% w/w to 0.30% w/w, or both betamethasone and mycophenolic acid or their salts.

Pharmaceutical compositions and methods for treating ocular disorders in a subject, which include betamethasone or a pharmaceutically acceptable salt thereof at a concentration of 0.01% w/w to 0.08% w/w, mycophenolic acid or a pharmaceutically acceptable salt thereof at a concentration of 0.05% w/w to 0.30% w/w, or both betamethasone and mycophenolic acid or their salts.

The present invention relates to compositions and formulations of polybasic drugs to reduce multiorgan toxicity by making supramolecular cationic complex without covalent bond formation, without conjugation and without chemical modification of macromolecular entity used. The compositions and formulations made thereof act by multiple mechanisms simultaneously to reduce toxicity of cationic antibiotic drugs.

The present invention relates to compositions and formulations of polybasic drugs to reduce multiorgan toxicity by making supramolecular cationic complex without covalent bond formation, without conjugation and without chemical modification of macromolecular entity used. The compositions and formulations made thereof act by multiple mechanisms simultaneously to reduce toxicity of cationic antibiotic drugs.

Delivering a payload across a plasma membrane of a cell includes providing a population of cells and contacting the population of cells with a volume of an aqueous solution. The aqueous solution includes the payload and alcohol content greater than 5 percent concentration. The volume of the aqueous solution may be a function of exposed surface area of the population of cells, or may be a function of a number of cells in the population of cells. Related compositions, apparatus, systems, techniques, and articles are also described.

The present disclosure provides a composition for submucosal injection including a divalent cation and an oligosaccharide obtained by exposing powdered polysaccharides to irradiation, heat, ultrasound, or ultraviolet radiation. The composition may be provided as a single solution; or the divalent cation and the oligosaccharide may be separately packaged, with the divalent cation being provided in solution form and the oligosaccharide being provided in powder form. The divalent cation may be 0.1-0.5% w/v of Ca.sup.2+, Mg.sup.2+, Fe.sup.2+, Cu.sup.2+, Ba.sup.2+, Zn.sup.2+, or any combination thereof. The oligosaccharide may be 0.5-2% w/v of degraded sodium alginate, degraded xanthan gum, degraded dextran, degraded welan gum, degraded gellan gum, degraded diutan gum, or any combination thereof. When the divalent cation is in contact with the oligosaccharide, viscosity of the composition is greater than 1000 cP, and injection pressure of the composition falls within a range of 2.5-4 kgf.

The present disclosure provides a composition for submucosal injection including a divalent cation and an oligosaccharide obtained by exposing powdered polysaccharides to irradiation, heat, ultrasound, or ultraviolet radiation. The composition may be provided as a single solution; or the divalent cation and the oligosaccharide may be separately packaged, with the divalent cation being provided in solution form and the oligosaccharide being provided in powder form. The divalent cation may be 0.1-0.5% w/v of Ca.sup.2+, Mg.sup.2+, Fe.sup.2+, Cu.sup.2+, Ba.sup.2+, Zn.sup.2+, or any combination thereof. The oligosaccharide may be 0.5-2% w/v of degraded sodium alginate, degraded xanthan gum, degraded dextran, degraded welan gum, degraded gellan gum, degraded diutan gum, or any combination thereof. When the divalent cation is in contact with the oligosaccharide, viscosity of the composition is greater than 1000 cP, and injection pressure of the composition falls within a range of 2.5-4 kgf.

The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.

The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.